Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Bimatoprost Ophthalmic Solution 0.03% for Glaucoma Articles

Watson confirms Lumigan and Latisse patent challenges; favorable Sanctura ruling

5 April 2012

Allergan's profit falls 58% as Botox sales drop

5 May 2009

Allergan's 4th-qtr profit falls 6% on 3% sales drop

16 February 2009

Stock Commentary - New York week to Dec 8, 2008

15 December 2008

Allergan's Ganfort beats Xalacom in trial

9 June 2008

Allergan gains FDA appro for Combigan

12 November 2007

EC approval for Allergan

5 June 2006

NZ: lifetime Special Authority for Lipitor users

22 August 2005

Approvable letter for Allergan

9 August 2004

Allergan and Senju sign Lumigan deal

31 May 2004

Allergan's Lumigan backed by CPMP

21 November 2001

Allergan to set up R&D center in France

10 September 2001

Competition hots up in US glaucoma market

26 March 2001

Allergan legal action against Pharmacia

2 March 2001

Allergan's Lumigan "better than timolol"

26 October 2000

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS